​

EyePoint Pharmaceuticals Ownership | Who Owns EyePoint Pharmaceuticals?

OverviewForecastRevenueFinancialsChartTranscripts

EyePoint Pharmaceuticals Ownership Summary

EyePoint Pharmaceuticals is owned by 107.82% institutional investors, 3.58% insiders. Suvretta capital management is the largest institutional shareholder, holding 9.65% of EYPT shares. Federated Hermes Kaufmann R is the top mutual fund, with 3.31% of its assets in EyePoint Pharmaceuticals shares.

EYPT Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockEyePoint Pharmaceuticals107.82%3.58%-11.40%
SectorHealthcare Stocks 244.59%12.11%-156.70%
IndustryBiotech Stocks 379.61%11.70%-291.31%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Suvretta capital management8.30M9.65%$118.64M
Blackrock funding, inc. /de7.46M8.68%$106.72M
Cormorant asset management, lp7.00M8.14%$100.10M
Blackrock3.76M7.12%$32.75M
Vanguard group4.82M6.87%$88.10M
Federated hermes5.68M6.61%$81.24M
Adage capital partners gp4.83M5.61%$69.04M
Franklin resources4.81M5.59%$68.74M
Commodore capital lp4.60M5.35%$65.78M
Janus henderson group3.60M4.34%$46.42M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Essex woodlands management1.08M6.10%$15.51M
Principia wealth advisory530.73K6.06%$9.70M
Rosalind advisors988.23K5.25%$14.13M
5am venture management1.05M5.22%$15.02M
Cormorant asset management, lp7.00M5.13%$100.10M
Commodore capital lp4.60M3.92%$65.78M
Suvretta capital management8.30M2.17%$118.64M
Artia global partners lp767.10K2.02%$10.97M
Parkman healthcare partners1.29M1.89%$18.42M
Blue owl capital lp762.59K1.64%$10.91M

Top Buyers

HolderShares% AssetsChange
Commodore capital lp4.60M3.92%1.77M
Adage capital partners gp4.83M0.10%1.53M
Vanguard group4.82M0.00%1.03M
Blackrock3.76M0.00%977.52K
Two sigma investments, lp1.18M0.01%750.83K

Top Sellers

HolderShares% AssetsChange
Tcg crossover management---3.57M
Ra capital management---3.18M
Perceptive advisors---1.54M
Cormorant asset management, lp7.00M5.13%-1.26M
Octagon capital advisors lp---1.09M

New Positions

HolderShares% AssetsChangeValue
Sixth street partners management company647.61K0.00%647.61K$9.26M
Ghisallo capital management350.00K0.10%350.00K$5.00M
Eversept partners, lp297.74K0.22%297.74K$4.26M
Axa investment managers244.43K0.01%244.43K$3.48M
Algert global78.99K0.01%78.99K$1.13M

Sold Out

HolderChange
Hughes financial services-1.00
Twin peaks wealth advisors-1.00
Root financial partners-5.00
Mai capital management-15.00
Assetmark-15.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 20262071.97%92,720,1064.60%1070.95%93-26.77%6062.16%
Mar 31, 202684-51.45%18,494,025-77.84%220.16%46-54.46%20-48.72%
Dec 31, 2025112-30.00%40,465,600-42.11%570.58%64-15.79%24-46.67%
Sep 30, 20251569.86%65,594,5981.78%931.10%767.04%4322.86%
Jun 30, 2025147-5.16%68,901,914-5.62%980.90%71-12.35%38-15.56%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Federated Hermes Kaufmann R2.77M3.31%-
Federated Hermes Kaufmann Growth2.77M3.21%-
Vanguard Total Stock Mkt Idx Inv2.64M3.16%43.00K
Vanguard Morn Total Stk Mkt Idx Investor2.64M3.16%43.00K
Vanguard MStar Total Stk Mkt Idx Invest2.64M3.07%-
Franklin Biotechnology Discv A(acc)USD2.08M2.41%158.65K
Federated Hermes Kaufmann Small Cap A1.98M2.36%-
iShares Russell 2000 ETF1.98M2.36%-35.14K
Federated Hermes Kaufmann Small Cap Grow1.98M2.30%-
Vanguard US Total Market Shares ETF1.56M2.27%-

Recent Insider Transactions

DateNameRoleActivityValue
Aug 18, 2026Zaderej Karen L.-Buy$52.26K
Jun 30, 2026Ribeiro Ramiro Chief Medical OfficerSell$36.55K
Jun 30, 2026Ribeiro Ramiro Chief Medical OfficerSell$36.61K
Apr 17, 2026Ribeiro Ramiro Chief Medical OfficerSell$36.55K
Mar 16, 2026Duker Jay S. President and CEOBuy$19.72K

Insider Transactions Trends

DateBuySell
2026 Q31-
2026 Q2-3
2026 Q113
2025 Q4-5
2025 Q3--

EYPT Ownership FAQ

Who Owns EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals shareholders are primarily institutional investors at 107.82%, followed by 3.58% insiders and -11.40% retail investors. The average institutional ownership in EyePoint Pharmaceuticals's industry, Biotech Stocks , is 379.61%, which EyePoint Pharmaceuticals falls below.

Who owns the most shares of EyePoint Pharmaceuticals?

EyePoint Pharmaceuticals’s largest shareholders are Suvretta capital management (8.3M shares, 9.65%), Blackrock funding, inc. /de (7.46M shares, 8.68%), and Cormorant asset management, lp (7M shares, 8.14%). Together, they hold 26.46% of EyePoint Pharmaceuticals’s total shares outstanding.

Does Blackrock own EyePoint Pharmaceuticals?

Yes, BlackRock owns 7.12% of EyePoint Pharmaceuticals, totaling 3.76M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 32.75M$. In the last quarter, BlackRock increased its holdings by 977.52K shares, a 35.07% change.

Who is EyePoint Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Essex woodlands management is EyePoint Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 6.10% of its assets in 1.08M EyePoint Pharmaceuticals shares, valued at 15.51M$.

Who is the top mutual fund holder of EyePoint Pharmaceuticals shares?

Federated Hermes Kaufmann R is the top mutual fund holder of EyePoint Pharmaceuticals shares, with 3.31% of its total shares outstanding invested in 2.77M EyePoint Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools